Colin F.. BMC Genomics. 2022. Publisher's page Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis Adriawan, Ignatius Ryan, Atschekzei, Faranaz, Dittrich-Breiholz [...] non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target Abere, Bizunesh, Mamo, Tamrat M., Hartmann, Silke, Samarina, Naira, Hage, Elias, Rückert

Araúzo-Bravo MJ, Vondran FWR , Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. 2021 Dec;75(6):1420-1433 [...] Seeliger B, Schmidt JJ, Wiesner O, Schmidt BMW, Taubert R, Vondran FWR , Hoeper MM, David S. Therapeutic plasma exchange in acute on chronic liver failure. J Clin Apher. 2020 Aug;35(4):316-327. doi: 10

1119363 Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle. Jäschke N, Büning H. Hematol Oncol Clin North Am 2022;36(4):667-685 DOI: 10.1016/j

Bokemeyer S, Haense C, Geworski L, Bengel FM, Müller-Vahl K. Evidence for an involvement and therapeutic relevance of the serotonergic system in Tourette syndrome with co-morbidities. Tagung der Europäischen

2020 DOI: 10.1038/s41523-020-0168-9 Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit Care 2020;24(1):363-020-03070-7 DOI: 10.1186/s13054-0 [...] A, Ranjbar E, Jahromi M, Seyedebrahimi R, Skripuletz T, Moharrami Kasmaie F. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic. Bi [...] SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe 2022 DOI: 10.1016/j.chom.2022.04.017 Siegerist F, Hay E, Dikou JS

, Middendorff, R., Loveland, K.L., Hedger, M.P., Meinhardt, A. (2019). Dexamethasone improves therapeutic outcomes in a preclinical bacterial epididymitis mouse model. Hum. Reprod. 34, 1195-1205. Scharf

Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett. 2012 Feb 17;586(4):310-3 Willjes G , Mahrhold S, Strotmeier

Acad Sci U S A. 2012 Apr 17. [Epub ahead of print] PubMed PMID: 22511722. Prinz I, Koenecke C. ; Therapeutic potential of induced and natural FoxP3+ regulatory T cells for the treatment of graft-versus-host

Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F , Rose-John S, Waetzig GH, Rosenstiel P. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory

Explored as Potential Treatment Option in Diabetic Retinopathy: Clinical Concept and Methodology.” Therapeutic Advances in Endocrinology and Metabolism 10:204201881989188. doi: 10.1177/2042018819891886. Trudzinski